Racura Oncology (ASX:RAC) said the potential of its proprietary formulation RC220 to prevent or slow resistance to osimertinib treatment in mutant epidermal growth factor receptor (EGFR) lung cancer will be explored in the clinic early this year, according to a Thursday filing with the Australian bourse.

Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined EGFR mutations, the company said in an earlier filing.

In-patient effect of the company's lead asset and anti-cancer agent RCDS1 (E,E-bisantrene) on master cancer growth regulator MYC will be evaluated later in the year, the filing said.

Shares of the company fell past 7% in recent Thursday trade.